GlassScriptPhysician profile
Afshin J Emami
NPI 1639123714
$8,303.57
in general payments reported to CMS, 2019-2025
22 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what 88% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $628 · 2021: $526 · 2022: $1,615 · 2023: $1,808 · 2024: $1,150 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,250 · Travel and Lodging: $490 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,249.53 |
| Travel and Lodging | $489.71 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $5,059.58 | 2019-2025 | Inspire |
| Stryker Corporation | $1,484.16 | 2019-2025 | Fiagon Navigation Unit, Xpress Ent Dilation System, Scopis Ent |
| Regeneron Healthcare Solutions, INC. | $223.82 | 2019-2025 | Dupixent |
| Acclarent, INC | $209.90 | 2020-2023 | Relieva Spinplus, Trudi Nav Cable |
| Genzyme Corporation | $207.48 | 2020-2025 | |
| Glaxosmithkline, LLC. | $192.21 | 2019-2023 | Nucala |
| Optinose US, INC. | $186.74 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $160.92 | 2022-2023 | Fasenra |
| Medtronic, INC. | $99.14 | 2021-2023 | Sinuva |
| Aerin Medical INC. | $77.07 | 2019-2022 | |
| Zoll Respicardia, INC. | $63.48 | 2022 | |
| Ethicon US, LLC | $58.03 | 2025 | Ethicon, Stratafix, Harmonic |
| Karl Storz Endoscopy-America | $53.30 | 2019 | |
| Intersect Ent, INC. | $49.04 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $46.26 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.88 | 2019 | |
| Hikma Pharmaceuticals USA | $20.98 | 2025 | Ryaltris |
| Arrinex, INC. | $18.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2021 | |
| Itamar Medical INC | $16.57 | 2022 | |
| Merck Sharp & Dohme LLC | $13.98 | 2021 | |
| 3b Medical, INC. | $12.90 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshin Emami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.